Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 10, 2025Frontiers in OncologyOpen Access

Total neoadjuvant chemoradiotherapy plus anti PD-1 for mid-to-low locally advanced rectal cancer: study protocol of a prospective, single arm, phase II study (STARS - RC06)

View Full Paper
Ask AI
Bookmark
Share

Authors

MGMeichen GuJilin UniversityYGYuchen GuoXidian UniversityLHLiang HeJilin University

Discussion

Loading...

Member takes

Implication

Prospective trial assesses pCR rates from neoadjuvant therapy combining chemoradiotherapy and immunotherapy, indicating potential for better outcomes.

Key Points

  • The trial aims to improve pCR rates in high-risk rectal cancer patients with combined therapies.
  • Targeting high-risk patients, the study evaluates the impact of neoadjuvant chemoradiotherapy on outcomes.
  • A single-arm phase II design focuses on assessing safety and efficacy within a specialized patient group.
  • Understanding this combination therapy may lead to better prognostic outcomes and organ preservation.

Cite This Study

Gu et al. (2025) studied this question.

synapsesocial.com/papers/68c1c64554b1d3bfb60f2784https://doi.org/10.3389/fonc.2025.1594927
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries2021 · 114,920 citations
  2. 2Efficacy and safety of PD-1 blockade plus long-course chemoradiotherapy in locally advanced rectal cancer (NECTAR): a multi-center phase 2 study2024 · 81 citations
  3. 3Total Neoadjuvant Therapy With PD-1 Blockade for High-Risk Proficient Mismatch Repair Rectal Cancer2024 · 53 citations